drugset
drugset / Trial / NCT02485249

Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema

NCT02485249 ↗

Phase 1/2 Terminated 25 enrolled Eyegate Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution, EGP-437, using the EyeGate® II Drug Delivery System (EGDS) in patients with macular edema (ME)

Timeline

Start
2015-07
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 mg/ml —

Indications

macular retinal edema